Huet, Heather,Ettenberg, Seth,Sussman, Django,Cheema, Tooba,Hickman, Taylor,O'Callaghan, Katie,Hyan, Maureen
申请号：
AU2018222741
公开号：
AU2018222741A1
申请日:
2018.02.16
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
Disclosed herein are methods of enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BCMA antibody and an effective amount of T lymphocytes and/or NK cells expressing an antibody-coupled T-cell receptor (ACTR) construct, which may comprises an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig)； a transmembrane domain； optionally one or more of co-stimulatory domains, and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM).
